Early corticosteroid withdrawal in recipients of renal allografts: A single-center report of ethnically diverse recipients and recipients of marginal deceased-donor kidneys

Transplantation

Volumn 94, Issue 8, 2012, Pages 837-844

  Aull, Meredith J ^a   Dadhania, Darshana ^a,b   Afaneh, Cheguevara ^a   Leeser, David B ^a   Hartono, Choli ^a,b   Lee, Jun B ^a,b   Serur, David ^a,b   Del Pizzo, Joseph J ^a   Suthanthiran, Manikkam ^a   Kapur, Sandip ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b ROGOSIN INSTITUTE   (United States)

Author keywords

African American; Corticosteroid withdrawal; Delayed graft function; Expanded criteria donor; Kidney transplant

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AFRICAN AMERICAN; ANTIGEN ANTIBODY REACTION; ARTICLE; CADAVER KIDNEY; COHORT ANALYSIS; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISPANIC; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PARASITOSIS; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ADULT; AFRICAN AMERICANS; AGED; DELAYED GRAFT FUNCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISPANIC AMERICANS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84868195358     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318265c461     Document Type: Article

References (31)

1. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
2. Luan FL, Steffick DE, Gadegbeku C, et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9: 160.
3. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
4. Boots JM, Christiaans MH, Van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703.
5. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845.
6. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppressionVa 5-year experience. Am J Transplant 2005; 5: 2473.
7. Woodle ES, FirstMR, Pirsch J, et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. 2008; 248: 564.
8. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetilVa prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865.
9. Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5: 87.
10. Khwaja K, Asolati M, Harmon JV, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004; 78: 1397.
11. Zeng X, El-Amm JM, Doshi MD, et al. Intermediate-term outcomes with early steroid withdrawal in African-American renal transplant recipients undergoing surveillance biopsy. Surgery 2007; 142: 538.
12. Pascual J, van Hooff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55.
13. Boardman RE, Alloway RR, Alexander JW, et al. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Transplant Proc 2005; 37: 814.
14. Alloway RR, Hanaway MJ, Trofe J, et al. A prospective, pilot study of early corticosteroid cessation in highYimmunologic-risk patients: the Cincinnati experience. Transplant Proc 2005; 37: 802.
15. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
16. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548.
17. Ioannidis JPA. Some main problems eroding the credibility and relevance of randomized trials. Bull NYU Hosp Jt Dis 2008; 66: 135.
18. Schold JD, Buccini LD, Goldfarb DA, et al. Patient participation in research among solid organ transplant recipients in the United States. Transplantation 2011; 91: 1424.
19. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
20. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999Y2008. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville,MD.
21. Sureshkumar KK, Thai NL, Hussain SM, et al. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on a steroid-free maintenance immunosuppression. Transplantation 2012; 93: 799.
22. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740.
23. Schold JD, Santos A, Rehman S, et al. The success of continued steroid avoidance after kidney transplantation in the US. Am J Transplant 2009; 9: 2768.
24. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81: 832.
25. Meier-KriescheHU,KazaH, Palekar SS, et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509.
26. Press R, Carrasquillo O, Nickolas T, et al. Race/ethnicity, poverty status, and renal transplant outcomes. Transplantation 2005; 80: 917.
27. Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844.
28. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050.
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(suppl 1): S62.
30. Serur D, Saal S, Wang J, et al. Deceased-donor kidney transplantation: improvement in long-term survival. Nephrol Dial Transplant 2011; 26: 317.
31. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62: 1060.